Investors2022-01-14T09:14:24+00:00

Investor Information

Stock Chart

View Listing

Investor News

  • PSYENCE_UPDATE_FEATURE

Psyence looks to expand capital market opportunities in the UK and Europe

January 21, 2022|

TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.

Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain

December 2, 2021|

Psyence is pleased to announce that its joint venture functional mushroom brand GOODMINDTM has partnered with one of Africa’s largest coffee retail chains, “vida e caffè”, to commence the rollout of its GOODMINDTM functional mushroom brand in select vida e caffè’s coffee shops in South Africa.

Investor News

Psyence Group Announces Private Placement

Psyence announces that it is commencing a non-brokered private placement offering of up to CAD$2,000,000 of unsecured convertible promissory notes (the “Notes”).

Dr Dingle Spence to speak at two conferences on psychedelics

Dr. Spence, an oncologist, palliative care specialist, and health justice activist will speak at the EndWell Conference – “The End in Mind – Psychedelic Medicines & Ending Well” taking place virtually on Thursday, October 14, 2021. Dr. Spence is also a featured speaker at the “Fantastic Fungi Global Summit – The Transformational Power of Mushrooms” taking place virtually on Friday, Saturday, and Sunday October 15-17th 2021.

Why Psyence?

Focused on natural psychedelics

  • Psyence Production: Producing natural psilocybin at our federally licensed facility built to GMP standards
  • Psyence Therapeutics: Proprietary natural psilocybin-based drug research & development as well as treatment protocols for treating psychological trauma and its mental health consequences
  • Psyence Wellness: Uniquely positioned to serve the mental wellness economy valued at $121B market by the Global Wellness Institute
  • Psyence Experience: Innovators in guided-psychedelic experiences

Operational

  • In 2020, Psyence was granted a licence by the Kingdom of Lesotho to cultivate and export psilocybin mushrooms. Our state-of-the-art facility is already operational and is on track for BSI and GMP certification.

Extensive capital markets/business building experience

  • Experienced global executive team
  • Our capital markets team (Bayline Capital Partners) has a track record for creating shareholder value and achieving sustainable growth

International expertise in palliative medicine and science

  • Our scientific and medical team includes Dr. Dingle Spence, a world-renowned expert in the palliative care, Dr. Amza Ali, an internationally recognized neurologist, Tammy Haynes, neuropsychologist, and Dr. Justin Grant, a leader in drug development.
  • Our Scientific Advisory Board is led by Psyence CEO Dr. Neil Maresky, physician and immediate past Vice President of Scientific Affairs at AstraZeneca Canada.

Extensive networks and partnerships

  • We are building partnerships with a network of institutions and companies including:
  • Government research centres
  • University hospitals and research centres
  • Regulatory stakeholders
  • Clinics, retreats and hospitality centres
  • Non-governmental organizations (NGOs)

An IP portfolio in cultivation and therapeutic products

  •  A mix of certified spores under cultivation
  • Psilocybin-based formulations with a focus on the anxiety and mental issues that come with end stage cancer under development
  • Micro-dose products under development to be launched in legal jurisdictions (entered into a JV in Brazil, formulating a truffle version for the Netherlands)

Functional mushroom brand

  • The launch of GOODMIND, the first functional mushroom brand in collaboration with the GoodLeaf Company. Launching our own proprietary Psyence Wellness products in 2021.

Downloads

View Presentation

Financial Statements

Psyence Group SEDAR Profile

Read Here

Psyence Group SEDAR Documents

Read Here

Corporate Details

Transfer Agent

Odyssey

Legal

Weirfoulds LLP

Auditor

MNP LLP

Why Psyence?

Focused on natural psychedelics

  • Psyence Production: Producing natural psilocybin at our federally licensed facility built to GMP standards
  • Psyence Therapeutics: Proprietary natural psilocybin-based drug research & development as well as treatment protocols for treating psychological trauma and its mental health consequences
  • Psyence Wellness: Uniquely positioned to serve the mental wellness economy valued at $121B market by the Global Wellness Institute
  • Psyence Experience: Innovators in guided-psychedelic experiences

Operational

  • In 2020, Psyence was granted a licence by the Kingdom of Lesotho to cultivate and export psilocybin mushrooms. Our state-of-the-art facility is already operational and is on track for BSI and GMP certification.

Extensive capital markets/business building experience

  • Experienced global executive team
  • Our capital markets team (Bayline Capital Partners) has a track record for creating shareholder value and achieving sustainable growth

International expertise in palliative medicine and science

  • Our scientific and medical team includes Dr. Dingle Spence, a world-renowned expert in the palliative care, Dr. Amza Ali, an internationally recognized neurologist, Tammy Haynes, neuropsychologist, and Dr. Justin Grant, a leader in drug development.
  • Our Scientific Advisory Board is led by Psyence CEO Dr. Neil Maresky, physician and immediate past Vice President of Scientific Affairs at AstraZeneca Canada.

Extensive networks and partnerships

  • We are building partnerships with a network of institutions and companies including:
  • Government research centres
  • University hospitals and research centres
  • Regulatory stakeholders
  • Clinics, retreats and hospitality centres
  • Non-governmental organizations (NGOs)

An IP portfolio in cultivation and therapeutic products

  •  A mix of certified spores under cultivation
  • Psilocybin-based formulations with a focus on the anxiety and mental issues that come with end stage cancer under development
  • Micro-dose products under development to be launched in legal jurisdictions (entered into a JV in Brazil, formulating a truffle version for the Netherlands)

Functional mushroom brand

  • The launch of GOODMIND, the first functional mushroom brand in collaboration with the GoodLeaf Company. Launching our own proprietary Psyence Wellness products in 2021.

Investor Sign-Up

Please enter your details below to receive investor updates on Psyence Group


By submitting this form, you are consenting to receive marketing emails from: Psyence Group Inc, 200 Bay Street, Toronto, ON, M5J2J1, https://www.psyence.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Downloads

View Presentation

Financial Statements

Psyence Group SEDAR Profile

Read Here

Psyence Group SEDAR Documents

Read Here

Corporate Details

Transfer Agent

Odyssey

Legal

Weirfoulds LLP

Auditor

MNP LLP
Go to Top